Evidence map›Paper›PMID 41649287›Full record

ArticlemSphere2026

Development of nanobody-conjugated LL37 for synergistic therapy against MDR

Apisitt Thaiprayoon, Worrapoj Oonanant, Siriphan Boonsilp, Nonth Submunkongtawee, Phoomintara Longsompurana, Duangtip Moonmangmee, Pinpunya Riangrungroj, Jeerapond Leelawattanachai, Lueacha Tabtimmai, Andrew C Kruse and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Apisitt ThaiprayoonBiological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, Thailand.
Worrapoj OonanantDepartment of Basic Medical Science, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.ORCID 0000-0002-3925-5321
Siriphan BoonsilpDepartment of Clinical Pathology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
Nonth SubmunkongtaweeBiological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, Thailand.
Phoomintara LongsompuranaBiological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, Thailand.
Duangtip MoonmangmeeDepartment of Microbiology, Faculty of Science, King Mongkut's University of Technology Thonburi, Bangkok, Thailand.
Pinpunya RiangrungrojNational Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Khlong Nueng, Pathum Thani, Thailand.
Jeerapond LeelawattanachaiNational Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Khlong Luang, Pathum Thani, Thailand.
Lueacha TabtimmaiDepartment of Biotechnology, Faculty of Applied Science, King Mongkut's University of Technology North Bangkok, Bangkok, Thailand.
Andrew C KruseDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
Matthew P DeLisaRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York, USA.
Phattara-Orn HavanapanInstitute of Molecular Biosciences, Mahidol University, Salaya, Nakhon Pathom, Thailand.
Dujduan Waraho-ZhmayevBiological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, Thailand.ORCID 0000-0003-4002-7817

Funding

National Research Council of Thailand NRCT5-RGJ63006Thailand Science Research and Innovation FRB690020/0164
6 · The paper itself

Abstract

Multidrug resistance (MDR) of the pathogen

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsCathelicidinsDrug Resistance, Multiple, BacterialSingle-Domain AntibodiesAcinetobacter InfectionsAntimicrobial Cationic PeptidesBacterial Outer Membrane ProteinsHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesBacterial Outer Membrane ProteinsCathelicidinsOMPA outer membrane proteinsSingle-Domain AntibodiesAcinetobacter baumanniiconjugated nanobodydrug-resistance bacteriaLL37MACS-based yeast displaynanobodyouter membrane protein A

Identifiers

PMID41649287
PMCPMC13037418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.